Similar Search Results

Evaluation and Learning in R&D Investment

Frankel, Alex; Krieger, Joshua L.; Li, Danielle; … - National Bureau of Economic Research - 2023

We examine the role of spillover learning in shaping the value of exploratory versus incremental R&D. Using data from drug development, we show that novel drug candidates generate more knowledge spillovers than incremental ones. Despite being less likely to reach regulatory approval, they are...

Persistent link: https://www.econbiz.de/10014287391

Quantifying the Social Value of a Universal COVID-19 Vaccine and Incentivizing Its Development

Glennerster, Rachel; Kelly, Thomas; McMahon, Claire T.; … - National Bureau of Economic Research - 2024

A booster of the COVID-19 vaccine targeting the prevailing Omicron variant did not become available in the United States until a year after the variant was first detected. This pattern of developing, testing, and distributing a variant-specific booster may become the default response to further...

Persistent link: https://www.econbiz.de/10014468259

Consequences of a Shortage and Rationing : Evidence from a Pediatric Vaccine

Liebman, Eli; Lawler, Emily C.; Dunn, Abe; Ridley, David B. - National Bureau of Economic Research - 2023

Shortages and rationing are common in health care, yet we know little about the consequences. We examine an 18-month shortage of the pediatric Haemophilus Influenzae Type B (Hib) vaccine. Using insurance claims data and variation in shortage exposure across birth cohorts, we find that the...

Persistent link: https://www.econbiz.de/10014322866

All Children Left Behind : Drug Adherence and the COVID-19 Pandemic

Feng, Josh; Higgins, Matthew J.; Patel, Elena - National Bureau of Economic Research - 2023

We study the effect of the COVID-19 pandemic on chronic disease drug adherence. Focusing on asthma, we use a database that tracks the vast majority of prescription drug claims in the U.S. from 2018 to 2020. Using a difference-in-differences empirical specification, we compare monthly drug...

Persistent link: https://www.econbiz.de/10014226165

The Effects of Off-label Drug Use on Disability and Medical Expenditure

Blankart, Katharina; Lichtenberg, Frank R. - National Bureau of Economic Research - 2022

Does using prescription drugs off-label increase disability and medical expenditure? This paper uses a unique dataset to evaluate off-label vs. on-label drug use in the US non-institutionalized population. Patients using drugs off-label have on average $515 higher medical expenditure and...

Persistent link: https://www.econbiz.de/10013388796

Auditing the Prescription Drug Consumer Price Index in a Changing Marketplace

Frank, Richard G.; Hicks, Andrew; Berndt, Ernst R. - National Bureau of Economic Research - 2022

prescription pharmaceuticals dispensed in hospitals, physician/clinic outpatient facilities, and nursing homes. Thus the CPI …-Rx overlooks the increasingly important specialty pharmaceuticals dispensed in hospitals, outpatient clinics, and physician offices … drug growth differs from that of traditional pharmaceuticals, the CPI-Rx could provide an inaccurate measure of overall …

Persistent link: https://www.econbiz.de/10013388804

Centralization and Organization Reproduction : Ethnic Innovation in R&D Centers and Satellite Locations

Kerr, William R. - National Bureau of Economic Research - 2023

We study the relationship between firm centralization and organizational reproduction in satellite locations. For decentralized firms, the ethnic compositions of inventors in satellite locations mostly resemble their host cities, with little link to the inventor composition of their parent...

Persistent link: https://www.econbiz.de/10014372481

Moonshot : Public R&D and Growth

Kantor, Shawn Everett; Whalley, Alexander T. - National Bureau of Economic Research - 2023

We estimate the long-term effect of public R&D on growth in manufacturing by analyzing new data from the Cold War era Space Race. We develop a novel empirical strategy that leverages US-Soviet rivalry in space technology to isolate windfall R&D spending. Our results demonstrate that public R&D...

Persistent link: https://www.econbiz.de/10014322858

The Role of Assets In Place : Loss of Market Exclusivity and Investment

Higgins, Matthew J. - 2020

We utilize a novel identification strategy to analyze the impact of assets in place on firms' decisions for future projects. We exploit the context in the pharmaceutical industry, where the loss of market exclusivity for a branded drug can be used to separate the impact of cash flows generated...

Persistent link: https://www.econbiz.de/10012481442

Expected Profits and The Scientific Novelty of Innovation

Dranove, David - 2020

Innovation policy involves trading off monopoly output and pricing in the short run in exchange for incentives for firms to develop new products in the future. While existing research demonstrates that expected profits fuel R&D investments, little is known about the novelty of the projects...

Persistent link: https://www.econbiz.de/10012481677

1
2
3
4
5
6
7
8
9
10
Next
Last